Clinical Research Headquarters
929 North Front Street
PPD is part of Thermo Fisher Scientific. As the world’s leader in serving science, our professionals develop critical solutions—and build rewarding careers. We offer services and products that help customers around the globe in laboratories and clinics, on production lines and out in the field.
We’re a driving force in the research, healthcare, industrial and applied markets, generating more $35 billion in annual revenue. No other company can match our range of customer touch points—technologically, geographically or commercially. We help customers in finding cures for cancer, protecting the environment, bringing medicines to market, making sure our food is safe and moving forward with thousands of important projects that improve millions of lives.
Stock Symbol: TMO
Stock Exchange: NYSE
Find PPD on social media:
Find PPD Careers on social media:
We All Have Our Why | PPD
444 articles about PPD
The PPD clinical research business of Thermo Fisher Scientific Inc., the world leader in serving science, has been awarded the Eagle Award for the second consecutive year for its outstanding leadership, professionalism, integrity and dedication to advancing the clinical research profession through strong partnerships with research sites.
The PPD clinical research business of Thermo Fisher Scientific Inc., the world leader in serving science, announced the creation of the PPD DCT Network to support global investigators and research sites participating in decentralized clinical trials (DCTs) for pharmaceutical and biotech customers.
Thermo Fisher Scientific’s PPD Clinical Research Business Selected to Support National Cancer Institute’s Cancer Trials Support Unit
Thermo Fisher Scientific’s PPD Clinical Research Business Selected to Support National Cancer Institute’s Cancer Trials Support Unit.
Thermo Fisher Scientific’s Clinical Research Business Named Clinical Research Company of the Year for Third Consecutive Year
The PPD clinical research business of Thermo Fisher Scientific has been named Clinical Research Company of the Year at the 2022 PharmaTimes Clinical Researcher of the Year International competition held recently in London.
Thermo Fisher Scientific Enhances Clinical Research Solutions in Collaboration with Matrix Clinical Trials
The PPD clinical research business of Thermo Fisher Scientific Inc. and Matrix Clinical Trials, a Matrix Medical Network offering, are collaborating to bring clinical trials to patients with an innovative decentralized clinical trial (DCT) solution.
PPD, Inc. (Nasdaq: PPD ), a leading global contract research organization, today reported its financial results for the third quarter ended September 30, 2021.
PPD, Inc. will host a conference call on Thursday, October 28, 2021, at 8 a.m. (U.S. Eastern Time) to discuss its third quarter 2021 financial results.
Aethlon Medical, Inc., a company developing medical technology to treat cancer and life-threatening infectious disease, announced that it has entered into an agreement with PPD, Inc., a leading global contract research organization, for PPD to oversee the company's clinical studies investigating the Hemopurifier, Aethlon's therapeutic blood filtration system, for infectious disease indications.
PPD, Inc. (Nasdaq: PPD ) has been recognized with two global excellence awards for its effective learning programs, honoring the company’s high-performing employee development initiatives supporting delivery of global operational excellence and innovative solutions to customers.
PPD, Inc.PPD, Inc., a leading global contract research organization, reported its financial results for the second quarter ended June 30, 2021.
PPD, Inc. will host a conference call on Thursday, July 29, 2021, at 7 a.m. (U.S. Eastern Time) to discuss its second quarter 2021 financial results.
PPD, Inc. (Nasdaq: PPD ) has been named “Most Innovative CRO” by North Carolina’s Triangle Business Journal , recognizing the global contract research organization’s strong performance in a year shaped by the COVID-19 pandemic.
PPD, Inc., a leading global contract research organization, held a grand opening ceremony for its new multipurpose laboratory in Suzhou, China, to support Western and China-based pharmaceutical and biotech companies managing China research studies.
PPD, Inc. has been recognized for excellence in the CRO Leadership Awards for the 10th consecutive year, earning praise for its clinical research capabilities and customer compatibility in a survey of pharmaceutical and biotech professionals conducted for Clinical Leader and Life Science Leader magazines.
PPD, Inc. was named “Best Contract Research Organization” at the 14th annual Vaccine Industry Excellence Awards during the 2021 World Vaccine Congress.
PPD, Inc., a leading global contract research organization, is expanding its Athlone, Ireland, GMP laboratory, significantly increasing the size of its current facility and adding cell and gene therapy testing to the operation’s portfolio of services.
PPD, Inc., a leading global contract research organization, reported its financial results for the first quarter ended March 31, 2021.
PPD and Science 37® Strengthen Collaboration to Advance Decentralized Clinical Trials and Accelerate Development
PPD, Inc. (Nasdaq: PPD), a leading global contract research organization (CRO), and Science 37, developer of the Decentralized Clinical Trial Operating System™ (DCT OS), today announced an innovative collaboration in which PPD will be fully enabled to design, build, test, implement and execute digital trials using Science 37's DCT SaaS-based technology platform.
Further expands service offering to pharma and biotech customers - Establishes Thermo Fisher as a global leader in the attractive and high growth clinical research services industry - Adds highly complementary services for the company's fastest growing end market
AzurRx BioPharma Engages PPD to Manage Clinical Trial for Niclosamide as Treatment for Grade 1 Immune Checkpoint Inhibitor-Associated ColitisPhase 1b/2a Study Expected to Begin In 2Q 2021
AzurRx BioPharma, Inc. (NASDAQ: AZRX ), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today that it has entered into an agreement with PPD, Inc. (NASDAQ: PPD ), a leading global contract research organization (CRO), for its planned Phase 1b/2a clinical trial